Elevar Presents CARES-310 Age Data at ILCA 2026

Elevar Therapeutics' post hoc analysis of the Phase 3 CARES-310 trial adds age-stratified survival data to the camrelizumab/rivoceranib dossier at a moment when the company is still pursuing FDA approval for the combination in unresectable hepatocellular carcinoma (uHCC). For regulatory affairs leads tracking the submission pathway, the dataset extends the efficacy narrative across a broader patient population without introducing new safety signals.

The exploratory analysis, presented as poster #P-106 at the International Liver Cancer Association (ILCA) 2026 Annual Conference in Brussels (September 3–5), examined outcomes by age subgroup. Camrelizumab, an anti-PD-1 antibody, combined with rivoceranib, an oral TKI, improved median overall survival (mOS) versus sorafenib in patients aged under 50 years (21.5 vs. 15.2 months; HR 0.7; P=0.0445) and 50 years or older (23.9 vs. 15.2 months; HR 0.6; P<0.0001). A numerically longer mOS was also observed in patients under 40 years (24.2 vs. 15.2 months; HR 0.82; P=0.2982), though that subgroup did not reach statistical significance.

Median progression-free survival (mPFS) improvements were consistent across all age cohorts: patients under 50 years (5.5 vs. 2.7 months; HR 0.53; P=0.0004), 50 years or older (6.2 vs. 3.7 months; HR 0.56; P<0.0001), and under 40 years (5.5 vs. 2.2 months; HR 0.56; P=0.0485). Median follow-up was 22.1 months. Treatment-related adverse events (TRAEs) were consistent across subgroups; the most common grade 3–4 TRAE for the combination was hypertension, while palmar-plantar erythrodysesthesia syndrome was most frequent for sorafenib.

Lead poster author Dr. Arndt Vogel of Toronto General Hospital Research Institute and UHN-Princess Margaret Cancer Centre noted the combination has been evaluated across early, intermediate, and advanced HCC stages, both as monotherapy and alongside locoregional therapies, with a manageable safety profile throughout. That breadth of investigation is relevant context for clinical operations and medical affairs teams building out the combination's positioning ahead of any potential label discussions.

Elevar, a majority-owned subsidiary of HLB Co., Ltd., is also sponsoring the ILCA welcome reception on September 3. The poster tour presentation is scheduled for September 4, 10:30–11:00 a.m. CET.

The regulatory trajectory for camrelizumab/rivoceranib in uHCC will become the more consequential data point once Elevar files or updates its FDA submission package.

Source: Elevar Therapeutics via GlobeNewswire, September 1, 2026.